Skip to main content
. 2020 Nov 3;12(11):724–733. doi: 10.14740/jocmr4351

Figure 5.

Figure 5

Time course effects of large IAD-eGFR (≥ 10%) after starting SGLT2i therapy on levels of 6 months eGFR in T2DM patients with CKD stage 3b. The line graph indicated serial changes in eGFR before and after treatment with SGLT2is according to the presence or absence of large IAD-eGFR (≥ 10%). eGFR: estimated glomerular filtration rate; IAD-eGFR: initial acute decline in eGFR; SGLT2i: sodium-glucose cotransporter-2 inhibitor; T2DM: type 2 diabetes mellitus; CKD: chronic kidney disease; SEM: standard error of mean.